In this proposal, the Division of Cardiology at Emory University seeks to become a Regional Clinical Center (RCC) within NHLBI's Heart Failure (HF) Clinical Research Network, a network of centers with active HF programs interested in generating and promoting evidence-based HF practice. Herein, we describe our HF and related programs, collaborators, and related clinical and research programs and institutions, our research and other accomplishments, and our faculty and key personnel;we also provide evidence of our institutional and individual expertise in clinical trials in HF, as well as documentation of access to relevant patient populations including women and minorities, extraordinary volume of HF patients, and multidi- sciplinary collaboration in the proposed Emory RCC. We believe that the Emory University infrastructure and investigators are well-equipped to achieve the primary and secondary goals of the Network. If chosen as a RCC, the Emory team will work diligently to achieve the various aims for the Network. We also seek to develop and implement a Clinical Research Skills Development Core to assist new investigators in developing their research skills, thus taking advantage of the rich environment presented by the Network and build upon the core of well trained clinical researchers within cardiovascular medicine focused on HF. As an indication of our ability to conceive, design, and conduct clinical trials, we also propose a randomized, placebo-controlled clinical trial (Nitric Oxide induced Vasodilation Evaluation in acute HF - NOVEL-HF) to evaluate the efficacy of the oral combination of hydralazine plus isosorbide dinitrate (H-ISDN) in patients with HF due to systolic dysfunction admitted with acute decompensated HF (AHDF). This therapy is associated with hemodynamic benefits that could improve outcomes in ADHF based on observational data. Emory University has a longstanding commitment to diversity and the population mix in the city of Atlanta offers a rich environment to study the similarities and differences in treatment among diverse patient groups. We therefore propose a clinical trial to assess a key clinical question facing HF medicine today, i.e. the role of H- ISDN in ADHF, its benefits and mechanisms of action, and outcomes in black versus non-black HF patients.

Public Health Relevance

Heart failure affects over 6 million Americans with a high mortality and hospitalization rate, and is currently a national healthcare priority. Emory, with a record of excellence in clinical and research programs for heart failure, an extraordinary clinical network, and a longstanding commitment to diversity, seeks to help improve outcomes for patients with heart failure by participating in NHLBI's Heart Failure Clinical Research Network.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10HL110302-02
Application #
8403730
Study Section
Special Emphasis Panel (ZHL1-CSR-K (O2))
Program Officer
Shah, Monica R
Project Start
2012-01-01
Project End
2018-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
2
Fiscal Year
2013
Total Cost
$356,500
Indirect Cost
$126,500
Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Vader, Justin M; LaRue, Shane J; Stevens, Susanna R et al. (2016) Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials. J Card Fail 22:875-883
Hamo, Carine E; Bloom, Michelle W; Cardinale, Daniela et al. (2016) Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. Circ Heart Fail 9:e002843
AbouEzzeddine, Omar F; Lala, Anuradha; Khazanie, Prateeti P et al. (2016) Evaluation of a provocative dyspnea severity score in acute heart failure. Am Heart J 172:34-41
Wan, Siu-Hin; Stevens, Susanna R; Borlaug, Barry A et al. (2016) Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circ Heart Fail 9:
Butler, Javed; Hernandez, Adrian F; Anstrom, Kevin J et al. (2016) Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. JACC Heart Fail 4:726-35
Butts, Brittany; Gary, Rebecca A; Dunbar, Sandra B et al. (2016) Methylation of Apoptosis-Associated Speck-Like Protein With a Caspase Recruitment Domain and Outcomes in Heart Failure. J Card Fail 22:340-6
Grodin, Justin L; Stevens, Susanna R; de Las Fuentes, Lisa et al. (2016) Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. J Card Fail 22:26-32
Bloom, Michelle W; Hamo, Carine E; Cardinale, Daniela et al. (2016) Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. Circ Heart Fail 9:e002661
Patel, Riyaz S; Ghasemzadeh, Nima; Eapen, Danny J et al. (2016) Novel Biomarker of Oxidative Stress Is Associated With Risk of Death in Patients With Coronary Artery Disease. Circulation 133:361-9
Margulies, Kenneth B; Hernandez, Adrian F; Redfield, Margaret M et al. (2016) Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA 316:500-8

Showing the most recent 10 out of 34 publications